BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 30982210)

  • 21. Risk of neoplastic progression in Barrett's esophagus diagnosed as indefinite for dysplasia: a nationwide cohort study.
    Kestens C; Leenders M; Offerhaus GJ; van Baal JW; Siersema PD
    Endoscopy; 2015 May; 47(5):409-14. PubMed ID: 25521571
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of dysplasia in patients with Barrett's esophagus based on expression pattern of 90 genes.
    Varghese S; Newton R; Ross-Innes CS; Lao-Sirieix P; Krishnadath KK; O'Donovan M; Novelli M; Wernisch L; Bergman J; Fitzgerald RC
    Gastroenterology; 2015 Nov; 149(6):1511-1518.e5. PubMed ID: 26248086
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Usefulness of insulin-like growth factor II mRNA-binding protein 3 (IMP3) as a new marker for the diagnosis of esophageal adenocarcinoma in challenging cases.
    Kazeminezhad B; Mirafsharieh SA; Dinyari K; Azizi D; Ebrahimi A
    Turk J Gastroenterol; 2014 Jun; 25(3):253-6. PubMed ID: 25141312
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The diagnosis and management of Barrett's esophagus.
    DeMeester SR; DeMeester TR
    Adv Surg; 1999; 33():29-68. PubMed ID: 10572561
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development and Validation of a Model to Determine Risk of Progression of Barrett's Esophagus to Neoplasia.
    Parasa S; Vennalaganti S; Gaddam S; Vennalaganti P; Young P; Gupta N; Thota P; Cash B; Mathur S; Sampliner R; Moawad F; Lieberman D; Bansal A; Kennedy KF; Vargo J; Falk G; Spaander M; Bruno M; Sharma P
    Gastroenterology; 2018 Apr; 154(5):1282-1289.e2. PubMed ID: 29273452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Longer inspection time is associated with increased detection of high-grade dysplasia and esophageal adenocarcinoma in Barrett's esophagus.
    Gupta N; Gaddam S; Wani SB; Bansal A; Rastogi A; Sharma P
    Gastrointest Endosc; 2012 Sep; 76(3):531-8. PubMed ID: 22732877
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Autofluorescence endoscopy in surveillance of Barrett's esophagus: a multicenter randomized trial on diagnostic efficacy.
    Borovicka J; Fischer J; Neuweiler J; Netzer P; Gschossmann J; Ehmann T; Bauerfeind P; Dorta G; Zürcher U; Binek J; Meyenberger C
    Endoscopy; 2006 Sep; 38(9):867-72. PubMed ID: 16981102
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of Mutational Testing of Preneoplastic Barrett's Mucosa by Next-Generation Sequencing of Formalin-Fixed, Paraffin-Embedded Endoscopic Samples for Detection of Concurrent Dysplasia and Adenocarcinoma in Barrett's Esophagus.
    Del Portillo A; Lagana SM; Yao Y; Uehara T; Jhala N; Ganguly T; Nagy P; Gutierrez J; Luna A; Abrams J; Liu Y; Brand R; Sepulveda JL; Falk GW; Sepulveda AR
    J Mol Diagn; 2015 Jul; 17(4):412-9. PubMed ID: 26068095
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection and staging of esophageal cancers within Barrett's esophagus is improved by assessment in specialized Barrett's units.
    Cameron GR; Jayasekera CS; Williams R; Macrae FA; Desmond PV; Taylor AC
    Gastrointest Endosc; 2014 Dec; 80(6):971-83.e1. PubMed ID: 24929493
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidence of Progression of Persistent Nondysplastic Barrett's Esophagus to Malignancy.
    Peters Y; Honing J; Kievit W; Kestens C; Pestman W; Nagtegaal ID; van der Post RS; Siersema PD
    Clin Gastroenterol Hepatol; 2019 Apr; 17(5):869-877.e5. PubMed ID: 30213587
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dysplasia in Random Biopsies from Barrett's Surveillance Is an Important Marker for More Severe Pathology.
    Noordzij IC; Van Loon van de Ende MCM; Curvers WL; van Lijnschoten G; Huysentruyt CJ; Schoon EJ
    Dig Dis Sci; 2021 Jun; 66(6):1957-1964. PubMed ID: 32661766
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased detection of Barrett's esophagus-associated neoplasia using wide-area trans-epithelial sampling: a multicenter, prospective, randomized trial.
    Vennalaganti PR; Kaul V; Wang KK; Falk GW; Shaheen NJ; Infantolino A; Johnson DA; Eisen G; Gerson LB; Smith MS; Iyer PG; Lightdale CJ; Schnoll-Sussman F; Gupta N; Gross SA; Abrams J; Haber GB; Chuttani R; Pleskow DK; Kothari S; Goldblum JR; Zhang Y; Sharma P
    Gastrointest Endosc; 2018 Feb; 87(2):348-355. PubMed ID: 28757316
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression analysis of Barrett's esophagus-associated high-grade dysplasia in laser capture microdissected archival tissue.
    Sabo E; Meitner PA; Tavares R; Corless CL; Lauwers GY; Moss SF; Resnick MB
    Clin Cancer Res; 2008 Oct; 14(20):6440-8. PubMed ID: 18927283
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increasing prevalence of high-grade dysplasia and adenocarcinoma on index endoscopy in Barrett's esophagus over the past 2 decades: data from a multicenter U.S. consortium.
    Desai M; Lieberman DA; Kennedy KF; Hamade N; Thota P; Parasa S; Gorrepati VS; Bansal A; Gupta N; Gaddam S; Young PE; Mathur S; Moawad FJ; Cash BD; Sampliner R; Vargo JJ; Falk GW; Sharma P
    Gastrointest Endosc; 2019 Feb; 89(2):257-263.e3. PubMed ID: 30342028
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alterations to the Esophageal Microbiome Associated with Progression from Barrett's Esophagus to Esophageal Adenocarcinoma.
    Snider EJ; Compres G; Freedberg DE; Khiabanian H; Nobel YR; Stump S; Uhlemann AC; Lightdale CJ; Abrams JA
    Cancer Epidemiol Biomarkers Prev; 2019 Oct; 28(10):1687-1693. PubMed ID: 31466948
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A cross sectional study of p504s, CD133, and Twist expression in the esophageal metaplasia dysplasia adenocarcinoma sequence.
    Ahmad J; Arthur K; Maxwell P; Kennedy A; Johnston BT; Murray L; McManus DT
    Dis Esophagus; 2015 Apr; 28(3):276-82. PubMed ID: 24612412
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association between length of Barrett's esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia.
    Anaparthy R; Gaddam S; Kanakadandi V; Alsop BR; Gupta N; Higbee AD; Wani SB; Singh M; Rastogi A; Bansal A; Cash BD; Young PE; Lieberman DA; Falk GW; Vargo JJ; Thota P; Sampliner RE; Sharma P
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1430-6. PubMed ID: 23707463
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Tissue Systems Pathology Assay for High-Risk Barrett's Esophagus.
    Critchley-Thorne RJ; Duits LC; Prichard JW; Davison JM; Jobe BA; Campbell BB; Zhang Y; Repa KA; Reese LM; Li J; Diehl DL; Jhala NC; Ginsberg G; DeMarshall M; Foxwell T; Zaidi AH; Lansing Taylor D; Rustgi AK; Bergman JJ; Falk GW
    Cancer Epidemiol Biomarkers Prev; 2016 Jun; 25(6):958-68. PubMed ID: 27197290
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Carbonic anhydrases II, IX, and XII in Barrett's esophagus and adenocarcinoma.
    Nortunen M; Huhta H; Helminen O; Parkkila S; Kauppila JH; Karttunen TJ; Saarnio J
    Virchows Arch; 2018 Nov; 473(5):567-575. PubMed ID: 30066203
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Editorial: Best Practices in Surveillance of Barrett's Esophagus.
    Wani S; Gaddam S
    Am J Gastroenterol; 2017 Jul; 112(7):1056-1060. PubMed ID: 28725066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.